Zoetis Inc (NYSE:ZTS) insider Heidi C. Chen sold 15,710 shares of Zoetis stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $95.49, for a total transaction of $1,500,147.90. Following the transaction, the insider now directly owns 13,963 shares in the company, valued at $1,333,326.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of Zoetis stock opened at $96.20 on Friday. The company has a current ratio of 3.60, a quick ratio of 2.46 and a debt-to-equity ratio of 2.95. Zoetis Inc has a 52-week low of $77.00 and a 52-week high of $97.95. The company has a market capitalization of $46.23 billion, a PE ratio of 30.73, a PEG ratio of 1.74 and a beta of 0.92.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 14th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.02. Zoetis had a net margin of 24.51% and a return on equity of 73.85%. The firm had revenue of $1.56 billion for the quarter, compared to analysts’ expectations of $1.53 billion. During the same quarter last year, the business earned $0.69 earnings per share. The business’s revenue was up 7.1% on a year-over-year basis. As a group, analysts predict that Zoetis Inc will post 3.46 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, June 3rd. Stockholders of record on Thursday, April 18th will be issued a $0.164 dividend. This represents a $0.66 annualized dividend and a dividend yield of 0.68%. The ex-dividend date is Wednesday, April 17th. Zoetis’s dividend payout ratio is 21.09%.

Zoetis announced that its board has authorized a stock repurchase plan on Wednesday, December 12th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 4.7% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Several research analysts have commented on ZTS shares. Zacks Investment Research downgraded shares of Zoetis from a “hold” rating to a “sell” rating in a research note on Monday, February 4th. UBS Group assumed coverage on shares of Zoetis in a report on Wednesday, January 23rd. They issued a “neutral” rating and a $86.00 target price on the stock. Stifel Nicolaus upgraded shares of Zoetis from a “hold” rating to a “buy” rating and raised their target price for the stock from $97.00 to $110.00 in a report on Monday, March 4th. Finally, BMO Capital Markets raised their target price on shares of Zoetis from $93.00 to $101.00 and gave the stock a “market perform” rating in a report on Monday, February 25th. Five analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $98.85.

A number of large investors have recently added to or reduced their stakes in ZTS. Oregon Public Employees Retirement Fund boosted its holdings in Zoetis by 9,042.7% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 14,335,563 shares of the company’s stock valued at $168,000 after acquiring an additional 14,178,765 shares in the last quarter. FMR LLC boosted its holdings in Zoetis by 209.7% in the fourth quarter. FMR LLC now owns 7,245,748 shares of the company’s stock valued at $619,801,000 after acquiring an additional 4,905,887 shares in the last quarter. Norges Bank bought a new stake in Zoetis in the fourth quarter valued at $404,080,000. Marshall Wace LLP boosted its holdings in Zoetis by 76.4% in the third quarter. Marshall Wace LLP now owns 3,216,573 shares of the company’s stock valued at $294,509,000 after acquiring an additional 1,393,397 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Zoetis by 206.5% in the third quarter. Renaissance Technologies LLC now owns 2,062,100 shares of the company’s stock valued at $188,806,000 after acquiring an additional 1,389,300 shares in the last quarter. Institutional investors and hedge funds own 89.98% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Insider Selling: Zoetis Inc (ZTS) Insider Sells 15,710 Shares of Stock” was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2019/03/15/insider-selling-zoetis-inc-zts-insider-sells-15710-shares-of-stock.html.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Recommended Story: How is the S&P 500 index different from the DJIA?

Insider Buying and Selling by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.